EA032779B1 - Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты - Google Patents

Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты Download PDF

Info

Publication number
EA032779B1
EA032779B1 EA201691789A EA201691789A EA032779B1 EA 032779 B1 EA032779 B1 EA 032779B1 EA 201691789 A EA201691789 A EA 201691789A EA 201691789 A EA201691789 A EA 201691789A EA 032779 B1 EA032779 B1 EA 032779B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
salt
present
syndrome
disease
Prior art date
Application number
EA201691789A
Other languages
English (en)
Russian (ru)
Other versions
EA201691789A1 (ru
Inventor
Мандар В. Дали
Джеймс Такасуги
Марла Л. Виталл
Эллен Уэлч
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201691789A1 publication Critical patent/EA201691789A1/ru
Publication of EA032779B1 publication Critical patent/EA032779B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
EA201691789A 2014-03-06 2015-03-05 Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты EA032779B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949052P 2014-03-06 2014-03-06
US201462009111P 2014-06-06 2014-06-06
PCT/US2015/018889 WO2015134711A1 (en) 2014-03-06 2015-03-05 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Publications (2)

Publication Number Publication Date
EA201691789A1 EA201691789A1 (ru) 2017-02-28
EA032779B1 true EA032779B1 (ru) 2019-07-31

Family

ID=54055864

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691789A EA032779B1 (ru) 2014-03-06 2015-03-05 Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты

Country Status (10)

Country Link
US (3) US9873677B2 (cg-RX-API-DMAC7.html)
EP (1) EP3113619A4 (cg-RX-API-DMAC7.html)
JP (3) JP6946001B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230024431A (cg-RX-API-DMAC7.html)
CN (3) CN106455571A (cg-RX-API-DMAC7.html)
CA (2) CA2942147C (cg-RX-API-DMAC7.html)
EA (1) EA032779B1 (cg-RX-API-DMAC7.html)
IL (1) IL247653B (cg-RX-API-DMAC7.html)
TW (2) TWI636978B (cg-RX-API-DMAC7.html)
WO (1) WO2015134711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235115C1 (en) 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
UA99600C2 (en) * 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
TW201729807A (zh) 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
CA3048202A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by inhibition of nonsense mediated decay
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2019101709A1 (en) 2017-11-23 2019-05-31 Universita' Degli Studi Di Palermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
CN109678715B (zh) * 2018-11-28 2019-11-12 中国药科大学 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
US10637694B1 (en) 2018-12-21 2020-04-28 At&T Intellectual Property I, L.P. Reduction and/or mitigation of spatial emissions in multi-antenna wireless communication systems for advanced networks
KR20210151131A (ko) 2019-04-10 2021-12-13 피티씨 테라퓨틱스, 인크. 소아 환자에서 넌센스 돌연변이 매개된 뒤센 근이영양증의 치료 방법
WO2022128876A1 (en) * 2020-12-14 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Ataluren eye drop formulation
US20250255816A1 (en) * 2022-04-18 2025-08-14 Vanderbilt University Polysulfide microparticles and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080114039A1 (en) * 2006-10-12 2008-05-15 Samit Hirawat Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US7419991B2 (en) * 2003-04-11 2008-09-02 Ptc Therapeutics, Inc. 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (cg-RX-API-DMAC7.html) 1962-04-17
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
EP0853626A1 (en) 1995-09-07 1998-07-22 Novartis AG Substituted phosphinic compounds and their use as pharmaceuticals
WO1997041105A1 (en) 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下3▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU9647998A (en) 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
IL139187A0 (en) 1998-04-23 2001-11-25 Cortech Inc Cysteine protease inhibitors
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
EP1119568B1 (en) 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
BR9916488A (pt) 1998-12-23 2001-10-09 Smithkline Beecham Corp Inibidores de protease
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
AU2001248765A1 (en) 2000-04-21 2001-11-12 Shionogi And Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0209054A (pt) 2001-04-19 2004-04-20 Bayer Ag Arilsulfonamidas como agentes antivirais
US7041685B2 (en) 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
EP1405636A4 (en) 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体-5调节剂的噁二唑
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのcetp阻害剤としての1,2,4−置換1,2,3,4−テトラヒドロ−および1,2−ジヒドロ−キノリンおよび1,2,3,4−テトラヒドロ−キノキサリン誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
JP5255183B2 (ja) 2003-09-04 2013-08-07 ウォックハート リミテッド ベンゾキノリジン−2−カルボン酸アルギニン塩四水和物
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005097096A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
JP2008515992A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
CN101193632A (zh) * 2005-04-08 2008-06-04 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
AU2006235115C1 (en) * 2005-04-08 2013-02-28 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
EP2387995A1 (en) * 2006-03-30 2011-11-23 PTC Therapeutics, Inc. Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
NZ598012A (en) * 2006-09-08 2013-08-30 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
US8101641B2 (en) 2006-09-25 2012-01-24 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof
UA99600C2 (en) 2006-09-25 2012-09-10 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110177999A1 (en) 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2234625B8 (en) 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
MX2010010300A (es) * 2008-03-19 2010-10-26 Osi Pharm Inc Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
WO2010008831A2 (en) 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
NZ605452A (en) 2008-07-14 2014-05-30 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
WO2011072281A1 (en) * 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015188037A1 (en) 2014-06-06 2015-12-10 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419991B2 (en) * 2003-04-11 2008-09-02 Ptc Therapeutics, Inc. 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, compositions, and methods for the use thereof
US8486982B2 (en) * 2003-04-11 2013-07-16 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acids
US20080114039A1 (en) * 2006-10-12 2008-05-15 Samit Hirawat Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

Also Published As

Publication number Publication date
JP2021165299A (ja) 2021-10-14
US20170066730A1 (en) 2017-03-09
TW201620883A (zh) 2016-06-16
US9873677B2 (en) 2018-01-23
IL247653B (en) 2022-04-01
KR20230024431A (ko) 2023-02-20
JP2017507158A (ja) 2017-03-16
CA3174516A1 (en) 2015-09-11
TWI636978B (zh) 2018-10-01
JP2020045354A (ja) 2020-03-26
TWI695717B (zh) 2020-06-11
EP3113619A1 (en) 2017-01-11
CN112979575A (zh) 2021-06-18
IL247653A0 (en) 2016-11-30
EP3113619A4 (en) 2017-09-13
KR102497273B1 (ko) 2023-02-07
JP7335795B2 (ja) 2023-08-30
JP6946001B2 (ja) 2021-10-06
CN106455571A (zh) 2017-02-22
CA2942147A1 (en) 2015-09-11
US20180179170A1 (en) 2018-06-28
US10233161B2 (en) 2019-03-19
US10618877B2 (en) 2020-04-14
US20190152931A1 (en) 2019-05-23
EA201691789A1 (ru) 2017-02-28
KR20160122268A (ko) 2016-10-21
WO2015134711A1 (en) 2015-09-11
CN112979574A (zh) 2021-06-18
CA2942147C (en) 2022-12-13
TW201836605A (zh) 2018-10-16

Similar Documents

Publication Publication Date Title
US10618877B2 (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
KR20220000881A (ko) 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
US12622894B2 (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
WO2025106389A1 (en) New forms of lutein and their uses
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
WO2023192372A1 (en) Methods of treating sjögren-larssen syndrome
HK40058574A (en) Pharmaceutical compositions and salts of a 1,2,4- oxadiazole benzoic acid
HK40054075A (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CN106714803A (zh) 眼用混悬液制剂
WO2016047662A1 (ja) 脳卒中の治療剤
HK1230865A1 (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
EA052805B1 (ru) Ганаксолон для использования при лечении эпилептического статуса
HK1233540B (en) Ophthalmic suspension formulation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM